Validation of the eighth clinical American Joint Committee on Cancer stage grouping for esophageal cancer

Future Oncol. 2018 Jan;14(1):65-75. doi: 10.2217/fon-2017-0376. Epub 2017 Dec 13.

Abstract

Aim: To validate the American Joint Committee on Cancer (AJCC) clinical staging system for esophageal cancer using Surveillance, Epidemiology and End Results database.

Methods: Cancer-specific survival analyses for clinically-staged patients with esophageal cancer according to both seventh and eighth editions were conducted through Kaplan-Meier analysis.

Results: For cancer-specific survival according to both seventh and eighth clinical systems, p-values for pairwise comparisons were nonsignificant in many comparisons. C-index for adenocarcinoma was: 0.671 according to the seventh AJCC and 0.671 according to the clinical eighth AJCC. C-index for squamous cell carcinoma according to the seventh AJCC was: 0.634 and 0.643 according to clinical eighth AJCC.

Conclusion: Minimal improvement was achieved by the eighth clinical AJCC staging system for esophageal cancer.

Keywords: SEER; esophageal cancer; prognosis; staging.

MeSH terms

  • Adenocarcinoma / epidemiology
  • Adenocarcinoma / pathology*
  • Adult
  • Aged
  • Carcinoma, Squamous Cell / epidemiology
  • Carcinoma, Squamous Cell / pathology*
  • Disease-Free Survival
  • Esophageal Neoplasms / epidemiology
  • Esophageal Neoplasms / pathology*
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Staging / classification
  • Prognosis*
  • SEER Program
  • United States